How Will the Market React to Evotec SE (EVO) Stock Getting a Bullish Rating

Overall market sentiment has been high on Evotec SE (EVO) stock lately. EVO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Evotec SE has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on EVO!

See Full EVO Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With EVO Stock Today?

Evotec SE (EVO) stock is trading at $8.91 as of 10:31 AM on Monday, Dec 5, a drop of -$0.23, or -2.52% from the previous closing price of $9.14. The stock has traded between $8.91 and $9.06 so far today. Volume today is low. So far 23,223 shares have traded compared to average volume of 97,338 shares. To screen for more stocks like Evotec SE click here.

More About Evotec SE

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The majority of its revenue is derived from the EVT Execute segment. Click Here to get the full Stock Report for Evotec SE stock.